Immuneering (IMRX) Operating Leases (2020 - 2024)
Immuneering (IMRX) has 5 years of Operating Leases data on record, last reported at $4.2 million in Q3 2024.
- For Q3 2024, Operating Leases changed 0.0% year-over-year to $4.2 million; the TTM value through Sep 2024 reached $4.2 million, changed 0.0%, while the annual FY2023 figure was $4.2 million, 6.72% down from the prior year.
- Operating Leases reached $4.2 million in Q3 2024 per IMRX's latest filing, down from $4.3 million in the prior quarter.
- Across five years, Operating Leases topped out at $5.1 million in Q4 2021 and bottomed at $481965.0 in Q3 2021.
- Average Operating Leases over 5 years is $3.7 million, with a median of $4.4 million recorded in 2024.
- The widest YoY moves for Operating Leases: up 842.53% in 2022, down 12.33% in 2022.
- A 5-year view of Operating Leases shows it stood at $544767.0 in 2020, then soared by 834.51% to $5.1 million in 2021, then dropped by 12.33% to $4.5 million in 2022, then dropped by 6.72% to $4.2 million in 2023, then rose by 1.88% to $4.2 million in 2024.
- Per Business Quant database, its latest 3 readings for Operating Leases were $4.2 million in Q3 2024, $4.3 million in Q2 2024, and $4.4 million in Q1 2024.